Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06187493
Other study ID # diabetic kidney
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date December 31, 2025

Study information

Verified date December 2023
Source Assiut University
Contact Ismael alaraby
Phone +201007967808
Email drismael83@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Due to irrespective of the limitations associated with estimated glomerular filtration rate (eGFR), it is crucial to develop new treatments that can effectively address these concerns. So, this study aimed to compare the effectiveness of SGlT2i versus ACEi in the progression of diabetic kidney disease including progression of albuminuria. Doubling of serum creatinine and need for renal replacement therapy


Description:

Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) worldwide and continues to be the major contributor to kidney replacement therapy (KRT). Despite the significant decline in diabetes-related complications in recent decades, the same trend cannot be observed in chronic kidney disease (CKD) patients due to DKD that requires KRT. Hence, there exists a significant requirement for novel treatment approaches that can enhance glycemic control while minimizing the risk of hypoglycemia, as well as reducing cardiovascular and renal risks within this population. Irrespective of the limitations associated with estimated glomerular filtration rate (eGFR), it is crucial to develop new treatments that can effectively address these concerns. ACE inhibitors may delay the progression of nephropathy and reduce the risks of cardiovascular events in hypertensive patients with diabetes mellitus type I and type II. SGLT2i have become the new standard of care for slowing CKD progression in patients with type 2 diabetes mellitus (T2DM, due to their specific renal and cardiovascular protective effects that are independent of the main metabolic and glucose-lowering effects. Research questions: Q1. Is there a significant effect of ACEi in treatment of patients with diabetic kidney disease. Q2: Is there is a significant effect of SGLT2i in treatment of patients with diabetic kidney disease. Q3: Which is more significantly efficient in treatment of patients with diabetic kidney disease (ACEi versus SGLT2i)


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 70
Est. completion date December 31, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients that suffer from Diabetic kidney disease (DKD) Exclusion Criteria: - Genital mycotic infections - Urosepsis and Pyelonephritis - Lower limb amputation - diabetic Ketoacidosis - Euglycemic DKA - Acute Kidney Injury - Hypoglycemia - Fournier Gangrene - Hypersensitivity Reactions - Bone fracture - Bladder cancer - Hyperkalemia - Dyslipidemia

Study Design


Intervention

Drug:
lisinopril, enalapril
Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia.
dapagliflozin, empagliflozin
Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Outcome

Type Measure Description Time frame Safety issue
Primary prevention of the development of DKD and alter its natural progression. Primary Outcome:
Time to development of DKD: Measured as the time from randomization to the first occurrence of any of the following events:
Sustained (=3 months) albumin-to-creatinine ratio (UACR) =300 mg/g End-stage kidney disease (ESKD) requiring dialysis or kidney transplantation
Measurement Tools:
UACR: Measured in urine samples using commercial laboratory assays. eGFR: Estimated using creatinine levels and demographic data through formulas like CKD-EPI.
Cardiovascular events and mortality: Ascertained through medical records and national death registries.
Unit of Measure:
Time to DKD development: Years or months Change in UACR: mg/g eGFR decline: mL/min/1.73 m² per year Cardiovascular events and mortality: Incidence per 70patient-years
baseline=3 months-year
See also
  Status Clinical Trial Phase
Recruiting NCT06006689 - Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) Phase 2
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Not yet recruiting NCT06120569 - Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients N/A
Completed NCT02545049 - Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Phase 3
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Active, not recruiting NCT06176599 - Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis N/A
Recruiting NCT03716401 - Prognostic Imaging Biomarkers for Diabetic Kidney Disease
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT01377688 - Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes N/A
Active, not recruiting NCT05514548 - Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease Phase 2
Recruiting NCT05507892 - Renal Mechanism of SGLT2 Inhibition Phase 2
Not yet recruiting NCT05514184 - Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease N/A
Not yet recruiting NCT06049550 - The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
Active, not recruiting NCT04589351 - Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe Phase 3
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Suspended NCT01878045 - Mechanisms of Diabetic Kidney Disease in American Indians